Short answer
Keros Therapeutics, Inc. (KROS) filed an 8-K current report with the SEC on August 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial results for quarter ended June 30, 2026.
Keros Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results for quarter ended June 30, 2026
- Press release issued August 3, 2026 and furnished as Exhibit 99.1
- Exhibit 99.1 contains the substantive financial results and management commentary
Item EX-99.1 · Exhibit EX-99.1
- Q2 2026 net loss $28.7M, improving from $30.7M despite zero revenue
- R&D expense fell to $22.3M from $43.5M as elritercept costs shifted to Takeda
- Cash $257.6M, down from $287.4M at year-end, supporting operations into first half 2028
- Phase 2 rinvatercept trial in Duchenne muscular dystrophy initiated, with initial data expected in first half 2027
- Six-month net loss $52.4M versus $117.8M net income, reflecting absence of $195.4M prior-year license revenue
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Keros Therapeutics, Inc. 8-K filings
Get the next KROS 8-K as it lands
Follow KROS for push alerts, or ask the research agent what this filing means.